gefitinib has been researched along with oseltamivir in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (oseltamivir) | Trials (oseltamivir) | Recent Studies (post-2010) (oseltamivir) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 3,368 | 186 | 2,014 |
| Protein | Taxonomy | gefitinib (IC50) | oseltamivir (IC50) |
|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | 0.1104 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.2616 | |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | 2.0317 | |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 1.1344 | |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | 0.002 | |
| Neuraminidase | Influenza B virus (B/Lee/1940) | 0.005 | |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | 0.008 | |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | 0.0043 | |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | 0.0003 | |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | 0.003 | |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | 0.0016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hosseinpour Moghadam, A; Hosseinpour Moghadam, N; Rakhtshah, J; Saidijam, M; Salehzadeh, S; Tanzadehpanah, H | 1 |
1 review(s) available for gefitinib and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for gefitinib and oseltamivir
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Preparation of a highly stable drug carrier by efficient immobilization of human serum albumin (HSA) on drug-loaded magnetic iron oxide nanoparticles.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cell Proliferation; Chlorocebus aethiops; DNA; Drug Carriers; Drug Compounding; Drug Stability; Ferrosoferric Oxide; Gefitinib; HeLa Cells; Humans; Immobilized Proteins; Inhibitory Concentration 50; Magnetite Nanoparticles; Nevirapine; Organ Specificity; Oseltamivir; Serum Albumin, Human; Silicon Dioxide; Tenofovir; Vero Cells | 2019 |